Agilent to Acquire Resolution Bioscience

Cleary Gottlieb is serving as antitrust counsel to Agilent Technologies Inc. (Agilent), which announced on March 3, 2021, that it has entered into a definitive agreement to acquire Resolution Bioscience Inc. (Resolution Bioscience).

The acquisition complements and expands Agilent’s capabilities in next-generation sequencing (NGS)-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Under the terms of the agreement, Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones.

Resolution Bioscience is a leader in the development and commercialization of NGS-based precision oncology solutions.